GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bafna Pharmaceuticals Ltd (BOM:532989) » Definitions » Debt-to-Revenue

Bafna Pharmaceuticals (BOM:532989) Debt-to-Revenue : 0.00 (As of Dec. 2023)


View and export this data going back to 2008. Start your Free Trial

What is Bafna Pharmaceuticals Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Bafna Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₹0 Mil. Bafna Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₹0 Mil. Bafna Pharmaceuticals's annualized Revenue for the quarter that ended in Dec. 2023 was ₹1,138 Mil. Bafna Pharmaceuticals's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 0.00.


Bafna Pharmaceuticals Debt-to-Revenue Historical Data

The historical data trend for Bafna Pharmaceuticals's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bafna Pharmaceuticals Debt-to-Revenue Chart

Bafna Pharmaceuticals Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.06 0.07 0.18 0.13 0.20

Bafna Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.14 - 0.10 -

Competitive Comparison of Bafna Pharmaceuticals's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Bafna Pharmaceuticals's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bafna Pharmaceuticals's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bafna Pharmaceuticals's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Bafna Pharmaceuticals's Debt-to-Revenue falls into.



Bafna Pharmaceuticals Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Bafna Pharmaceuticals's Debt-to-Revenue for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(144.906 + 84.333) / 1153.499
=0.20

Bafna Pharmaceuticals's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0 + 0) / 1137.688
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2023) Revenue data.


Bafna Pharmaceuticals Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Bafna Pharmaceuticals's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Bafna Pharmaceuticals (BOM:532989) Business Description

Traded in Other Exchanges
Address
Thambu Chetty Street, New No. 68, Old No.299, Bafna Towers, Chennai, TN, IND, 600001
Bafna Pharmaceuticals Ltd is an India-based pharmaceutical company. It is principally engaged in the manufacturing and marketing of drugs and medicines. The company sells its products in India and international regions. The company has only one Segment of Business namely Pharmaceuticals.

Bafna Pharmaceuticals (BOM:532989) Headlines

No Headlines